Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash Flows From Investing Activities: | ||
| Proceeds from maturities of marketable securities | 118,404 | 170,218 |
| Purchases of marketable securities | (129,201) | (255,273) |
| Purchases of property and equipment | (9,887) | (1,591) |
| Net cash used in investing activities | (20,684) | (86,646) |
| Cash Flows From Financing Activities: | ||
| Proceeds from issuance of common stock, net of paid issuance costs | — | 134,771 |
| Proceeds from sale of common stock under employee stock purchase plan | 1,438 | 1,101 |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s capex?
- Tarsus Pharmaceuticals, Inc. (TARS) reported capex of $4.07M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s capex changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s capex increased by 306.5% year-over-year, from $1M to $4.07M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s capex?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s capex has grown at a 102.5% compound annual growth rate (CAGR), from $586K to $9.86M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude